CD274 and non-small cell lung carcinoma: Within the framework of the KEYNOTE-024 trial, the ORR for PD-L1 ≥ 50% NSCLC patients receiving Pembrolizumab was a mere 44.8%, thereby indicating a considerable proportion of individuals with heightened PD-L1 expression did not manifest a response to this treatment (28).